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Antibiotics are critical to the treatment of bacterial
infections. However, after years of overuse and misuse of
these drugs, bacteria have developed antibiotic resistance,
which has become a global health crisis (1, 2). The relatively
recent increase of surface antibacterial agents or biocides into
healthy households may contribute to the resistance problem.
The antibacterial substances added to diverse household
cleaning products are similar to antibiotics in many ways. When
used correctly, they inhibit bacterial growth. However, their
purpose is not to cure disease but to prevent transmission of
disease-causing microorganisms to noninfected persons. Like
antibiotics, these products can select resistant strains and,
therefore, overuse in the home can be expected to propagate
resistant microbial variants (3-6). Moreover, these agents, like
antibiotics, are not cure-alls but have a designated purpose.
Whereas antibiotics are designed to treat bacterial (not viral)
infections, antibacterial products protect vulnerable patients
from infectious disease-causing organisms. Neither are
demonstrably useful in the healthy household.
Proliferation of Antibacterial Products
Seven years ago, only a few dozen products containing
antibacterial agents were being marketed for the home. Now
more than 700 are available. The public is being bombarded
with ads for cleansers, soaps, toothbrushes, dishwashing
detergents, and hand lotions, all containing antibacterial
agents. Likewise, we hear about “superbugs” and deadly
viruses. Germs have become the buzzword for a danger people
want to eliminate from their surroundings. In response to
these messages, people are buying antibacterial products
because they think these products offer health protection for
them and their families. Among the newer products in the
antibacterial craze are antibacterial window cleaner and
antibacterial chopsticks. Antibacterial agents are now in
plastic food storage containers in England. In Italy,
antibacterial products are touted in public laundries. In the
Boston area, you can purchase a mattress completely
impregnated with an antibacterial agent. Whole bathrooms
and bedrooms can be outfitted with products containing
triclosan (a common antibacterial agent), including pillows,
sheets, towels, and slippers.
Development of Resistance
Bacteria are not about to succumb to this deluge,
however. Through mutation, some of their progeny emerge
with resistance to the antibacterial agent aimed at it, and
possibly to other antimicrobial agents as well (4). Laboratory-
derived mutants of Pseudomonas stutzeri with resistance to
the cationic biocide chlorhexidine were also cross-resistant to
antibiotics (nalidixic acid, erythromycin, and ampicillin) (7).
In a recent study, 7% of Listeria monocytogenes strains
isolated from the environment and food products showed
resistance to quaternary ammonium compounds (8).
Laura McMurry in my laboratory group conducted
experiments to determine whether triclosan had a particular
cellular site for its antibacterial activity. She used a classic
genetic technique, the isolation of resistant mutants of
Escherichia coli, to identify its possible target. Surprisingly,
finding the cellular site proved easy. In fact, mutants appeared
with low, medium, and high-level resistance (3). They all had a
mutation in one gene, the fabI gene (3) (Table 1). This finding
indicated that triclosan had a target for the enoyl reductase
essential in fatty acid biosynthesis. In the presence of triclosan,
or a known FabI inhibitor (diazoborine), fatty acid biosynthesis
was inhibited, whereas the antibiotics chloramphenicol or
ciprofloxacin with other targets had little effect on fatty acid
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Table 1. Selection of Escherichia coli with triclosan resistance (3)
MIC Change Mutated
E. coli (µg/ml) (fold) gene
AG100 0.05 1.0 ——
AG100-1 0.20 4.0 fabI (F203L)
AG100-2 1.90 40.0 fabI (M159T)
AG100-3 25.00 500.0 fabI (G93V)513 Vol. 7, No. 3 Supplement, June 2001 Emerging Infectious Diseases
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Table 3. Effect of triclosan in soap on Escherichia colia
In nutrient broth
Strain In nutrient broth with commercial soap
AG100b 6 150
AGT11c >32 300-600
a Amount (µg/ml) needed to kill 90% of E. coli (2 h at 37°C).
b Wild-type
c Mutant
Table 4. Mutations in InhA confer triclosan resistance in Mycobacterium
smegmatis (9)
Relative MIC
InhA (in 7H9 medium)
Strain Selected ona mutation TRC INH
mc2155 (wt) — None 1.0 1.0
MT 1 TRC M161V 6.3 8.5
MT 9 TRC M103T 6.3 1.2
MT 17 TRC A124V 5.8 2.0
mc2651 INH S94A 6.3 22.0
mc2155 (p::inhA) — None 6.3 >64
aTRC, triclosan; INH, isoniazid
Table 5. Effect of triclosan in liquid culture on growth and lysis of
Escherichia coli strains with and without AcrAB efflux pump (4)
Concentration (µg/ml) that
Inhibited growth
Strain Characteristics 50% (90%) Caused lysis
AG100 Wild-type 0.15 (0.60) 8
AG100A AG100 0.02 (0.05) 3-4
acrAB::kan
AGT11 AG100 13.0        (>32) >32
fabI (G93V)
AGT11K AGT11 1.3 (2.10) 3-4
acrAB::kan
Table 2. Effect of various drugs on fatty acid/lipid synthesis in intact cells
Strain Drug µg/ml % inhibition
AG100 Triclosan 0.24 92
(wild-type) Diazaborine 8.0 93
Chloramphenicol 13.0 19
Ciprofloxacin 0.045 2
AGT11 Triclosan 0.24 2
(G93V) Triclosan 1.4 7
Triclosan 8.6 37
Triclosan 25.9 75
biosynthesis (Table 2). In comparison with the wild-type E. coli,
the mutant required up to 100 times more triclosan to show even
minimal inhibition of fatty acid biosynthesis (3).
One might argue that the high concentration of triclosan
usually found in soap, e.g. 2,500 µg/ml, is enough to kill even
resistant strains. We examined this question by testing
triclosan activity in a commercial soap. To achieve a 90%
death rate, wild-type E. coli required exposure to 150 µg/mL of
triclosan in soap for 2 hours at 37ºC. Two to four times that
amount was required by the mutant. By itself, triclosan was
more active, killing E. coli at 6 µg/ml, and there was an even
greater difference between the amounts required to kill wild-
type and mutant E. coli. The soap seemed to decrease
triclosan’s effectiveness (Table 3). The mutant E. coli strains
are truly resistant and would survive in triclosan-treated
soaps diluted with as little as 3 parts water. Most
importantly, the time, temperature, and amount needed to
kill the bacteria greatly exceeded the average 5-second hand
washing performed by most people.
The finding of a mutation in the fabI gene led to a study
of its homologue, inhA, the gene for one of the proposed targets
of isoniazid, an anti-tuberculosis drug. Whether selected in
triclosan or isoniazid, mutants of Mycobacterium smegmatis
showed cross-resistance to both drugs via a mutation in the
inhA gene (Table 4) (9). Moreover, triclosan-resistant E. coli
mutants also showed resistance to an experimental
antibiotic, diazoborine (3). Other drugs currently under
development may target fabI; these potentially new
antibiotics may also be affected by triclosan resistance.
The data clearly suggest that antibacterial agents will
have an impact on the environmental flora and on resistance
emergence. For instance, use of triclosan could select bacteria
which have intrinsic resistance to the chemical. Some gram-
positive bacteria such as Enterococcus faecalis and
Streptococcus pneumoniae, which do not have fabI, have a
related enoyl reductase gene, fabK (10). The fabK gene in
those organisms is naturally resistant to triclosan, so
triclosan usage can potentially enhance their growth at the
expense of susceptible strains. At the American Society for
Microbiology meetings in May 2000, a number of papers
described the isolation of bacteria resistant to triclosan or to
other antibacterial agents (11-13).
The other known mechanism by which bacteria resist
these drugs is by pumping them out of the cell by an efflux
mechanism. The key genes in E. coli involved in this form of
resistance are a regulatory gene, marA,and an efflux gene
complex,  acrAB (14). MarA is a component of a multiple
antibiotic resistance locus, marRAB. When marA is
activated, the cell becomes resistant to antibiotics, oxidative
stress agents, organic solvents, and antibacterial agents (14).
Over 60 different genes are affected when marA is
overexpressed in E. coli, indicating a very large regulon (15).
Strains that overproduce the marA or soxS protein (which is a
marA homologue) upregulate the AcrAB multidrug efflux
pump which pumps out pine oils, organic solvents, triclosan,
quaternary ammonium compounds, chloroxanol, and chlo-
rhexidine (4). Triclosan is also a substrate for multidrug
efflux pumps in Pseudomonas aeruginosa (16).
Efflux pumps can affect antibiotic efficacy in a number of
ways. A triclosan-resistant mutant of E. coli does not lyse
easily in the presence of triclosan, making the strain difficult
to kill. Triclosan lyses the wild-type cell (AG100) at about 8
µg/ml, but the mutant AGT11 requires at least four times that
amount (=32 µg/ml) (Table 5). When the acrAB gene locus is
deleted from the wild-type cell, lysis occurs at a lower
concentration, i.e., 3 to 4 µg/ml. More importantly, with
removal of the AcrAB pump, the mutant bacteria and the
wild-type cells were killed by the same amount of triclosan,
i.e., 3 to 4 µg/ml, despite residual fabI resistance in the
mutant to the growth inhibitory action of triclosan (Table 5).
Therefore, the normal expression of a multidrug efflux pump
in E. coli is critical to the activity of triclosan.514 Emerging Infectious Diseases Vol. 7, No. 3 Supplement, June 2001
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Mar mutants generally express low levels of antibiotic
resistance and are precursors to mutants with high-level
antibiotic resistance (14). We have identified clinical strains
of E. coli that are resistant to triclosan because they are also
Mar mutants (4). From these and other data, selection for Mar
mutants can potentially occur by antibiotics or by
antibacterial agents.
Consequences of Resistance
Community-acquired methicillin-resistant Staphylococ-
cus aureus (cMRSA) has become an increasing problem
worldwide. These community-derived strains show an
antibiotic susceptibility profile that is markedly different
from hospital-acquired MRSA. cMRSA strains are chiefly
resistant to the beta-lactam antibiotics (penicillins and
cepholosporins). Interesting laboratory findings suggest a
link between this resistance in cMRSA and the use of
antibacterial products. Investigators in Japan selected MRSA
mutants with a twofold higher minimal inhibitory
concentration for benzalkonium chloride (5 to 10 µg/ml) (17).
Resistance to methicillin and to a number of cephalosporins
and penicillins dramatically increased with this mutation
(Table 6), but susceptibility to other antibiotics was
essentially unchanged. The laboratory mutants, in fact,
mirror the phenotype of the MRSA that has emerged in the
community. Is there a connection?  The findings warrant
further study.
Antibacterial agents and antibiotics share the same
resistance problem. Resistance will certainly increase as the
drug persists, especially at low levels (e.g., residues) for long
periods of time. Of course, that concern is irrelevant with
substances that do not leave residues (e.g., alcohols, bleaches,
and peroxides). No current data demonstrate any health
benefits from having antibacterial-containing cleansers in a
healthy household. However, use of these products may
change the environmental microbial flora.
Unfortunately, the antibacterial indulgence is coincident
with the trend toward shorter hospital stays. An estimated
5% of hospital patients in Massachusetts go home for
continued care, often with intravenous parenteral drugs. For
these vulnerable patients, the use of antibacterial products
protects them from disease caused by commensal as well as
pathogenic bacteria. A cause for concern now is that homes,
which are becoming end-of-therapy quarters for patients, may
be becoming havens for “hospital-like” bacteria as well.
The Antibacterial Products-Allergy Link
Besides resistance, the antibacterial craze has another
potential consequence. Reports are mounting about a possible
association between infections in early childhood and
decreased incidence of allergies (18). In expanding this
“hygiene hypothesis,” some researchers have found a
correlation between too much hygiene and increased allergy
(18-21). This hypothesis stems from studies that revealed an
increased frequency of allergies, cases of asthma, and eczema
in persons who have been raised in an environment overly
protective against microorganisms. In one rural community,
children who grew up on farms had fewer allergies than did
their counterparts who did not live on farms (19). Graham
Rook, University College, London, has likened the immune
system to the brain. You have to exercise it, that is, expose it
to the right antigenic information so that it matures correctly.
Excessive hygiene, therefore, may interfere with the normal
maturation of the immune system by eliminating the
stimulation by commensal microflora (20).
For normal maturation, the immune system must be
stimulated to achieve the right balance between the T-helper
1 (TH-1) cells providing cellular immunity and the TH-2 cells
promoting antibody production. When investigators exam-
ined people with allergies and eczema, they noted an
imbalance between TH-2 and TH-1 activities as compared
with the mechanisms in control groups. In those with
allergies, antibody production predominated over cell-
mediated responses. Other studies showed a correlation
between the presence of an immune response to organisms
contracted by the oral-fecal route and decreased likelihood of
atopy (21). In those persons who demonstrated a prior
exposure to one, two, or all three of the organisms tested
(Toxoplasma gondii, Helicobacter pylori, hepatitis A virus),
the odds ratio for allergy became substantially lower than
that seen in the control group (21). This correlation was not
found for prior contact with organisms causing infections by
other routes (e.g., mumps, measles, varicella). The authors
concluded that “hygiene and a westernized, semi-sterile diet
may facilitate atopy by influencing the overall pattern of
commensals and pathogens that stimulate the gut-associated
lymphoid tissue …” (21). Of note, children vaccinated with
bacillus Calmette-Guérin appeared to be protected as well
against atopy (22), and this finding was also related to
stimulation of the TH-1 response. The combined data led one
group to conclude that an “antigenically rich (dirty)
environment may be essential for normal immune
maturation preventing atopic disease” (23).
Antibiotics may also be implicated in the hygiene
hypothesis. Because they eliminate common bacteria,
antibiotics may cause the same consequence as too much
hygiene. Some infants begin to get antibiotics as soon as a few
days after birth. They mature in an antibiotic-laden
environment. What antigens do they confront daily?  What
kind of immune response are they developing?
We must think not just in terms of resistance but also in
terms of the changes in the microbial ecology of our infants
and our homes. We exist in the bacterial world, not bacteria in
ours. Unfortunately, we believe that we can rid ourselves of
Table 6. Antibiotic susceptibility of methicillin-resistant Staphylococcus
aureus and benzalkonium chloride-resistant derivativesa
MRSAb
Antibiotic Parent BZ-R-1 BZ-R-2
Oxacillin 16.0 512 512
Cloxacillin 0.5 256 512
Moxalactam 64.0 256 1024
Flomoxef 8.0 128 128
Cefmetazole 8.0 128 64
Cephalothin 64.0 128 128
Ampicillin 16.0 32 32
Chloramphenicol 4.0 4 4
Ofloxacin 8.0 32 32
Tetracycline 128.0 128 128
Benzalkonium chloride 5.0 10 10
aAdapted from (17).
bMIC (µg/ml) (BZ-R = parent resistant to benzalkonium chloride)515 Vol. 7, No. 3 Supplement, June 2001 Emerging Infectious Diseases
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bacteria when, in fact, we cannot. Instead, we should “make
peace” with them. Although we need to control pathogens
when they cause disease, we do not have to engage in a full-
fledged “war” against the microbial world. Improved
antibiotic use, including shorter treatments and removal of
improper usage, will encourage the return of antibiotic-
susceptible, commensal flora and return the environment to
what it was before the antibiotic/antibacterial onslaught.
A new approach focusing on commensals has been initiated
through an agreement between the Alliance for Prudent Use of
Antibiotics (APUA) (www.apua.org) and the University of
Illinois, funded by the National Institute of Allergy and
Infectious Disease. This initiative, entitled ROAR (Reservoirs of
Antibiotic Resistance; http://www.roar.apua.org) focuses on
monitoring and managing the commensal bacteria that harbor
pools of resistance genes that can be passed on to pathogens.
Through education, APUA strives to foster control of pathogens
without decimation of the non-pathogens. In this goal, prudent
use applies to both antibiotics and antibacterial products.
Research in this laboratory has been supported through grants
from the National Institutes of Health.
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